Moreover, observational series and pooled analyses confirm that PCSK9 inhibitors are safe and effective in mild-to-moderate CKD, with LDL-C-driven benefits and preserved renal function, although data in eGFR <30 are still limited [172,173]. Here, PCSK9 is linked to chronic kidney disease.